From Lab to Large-Scale Production
Properties held constant from the first lab batch to pilot scale.
03/
Nanoparticles do not scale like conventional drugs: size, stability and release behavior can shift with every change in batch size. OmniParticles builds process development around that reality, refining formulation parameters, material selection and workflows and verifying each step with in-house analytics, so your formulation moves from early research to non-clinical and clinical manufacturing without losing what made it work.
Photos of equipment at OmniParticles
What we offer
1
Scale-up development
Over 1,000x scale-up from early-stage research to non-clinical and clinical manufacturing, preserving size uniformity, physicochemical properties and efficacy.
2
Characterization & composition analysis
DLS for hydrodynamic diameter, PDI and aggregation; TEM for size distribution, grain size and morphology with representative images; UV-Vis extinction spectra and zeta-potential for surface charge and colloidal stability; ICP-MS elemental composition of organic and inorganic samples down to parts per trillion, LC-MS and GPC for molecular weight, and HPLC (including SEC mode, triple detector).
3
Analytical method development
Customized methods for each stage, from rapid on-site size and morphology checks to ion quantification and stability testing.
4
Process validation & documentation
Reproducibility aligned with FDA and EMA expectations, backed by process development reports and tech transfer dossiers.
